<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517292</url>
  </required_header>
  <id_info>
    <org_study_id>GEP</org_study_id>
    <nct_id>NCT04517292</nct_id>
  </id_info>
  <brief_title>Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)</brief_title>
  <acronym>GEP</acronym>
  <official_title>A Phase II, Single-center, Randomized Study of Eribulin Plus Cisplatin (EP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer&#xD;
      (TNBC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, Single-center, Randomized Study of Eribulin Plus Cisplatin (EP) Versus&#xD;
      Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced&#xD;
      Triple-Negative Breast Cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 8, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>approximately 6 weeks</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>approximately 6 weeks</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>approximately 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Eribulin,cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EP (Eribulin and cisplatin combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine,cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GP (gemcitabine and cisplatin combination)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin,cisplatin</intervention_name>
    <description>Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1</description>
    <arm_group_label>Eribulin,cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine,cisplatin</intervention_name>
    <description>Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1</description>
    <arm_group_label>Gemcitabine,cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females with age between 18 and 70 years old&#xD;
&#xD;
          2. Histological proven unresectable recurrent or advanced breast cancer, including de&#xD;
             novo stage IV disease.&#xD;
&#xD;
          3. Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human&#xD;
             epithelial receptor-2 (HER2) by immunohistochemistry (ER &lt;1%, PR &lt;1% and Her2&#xD;
             negative). A negative Her2 gene amplification should be verified by FISH test for&#xD;
             those patients with Her2 (2+). For those with Her2 (1+), FISH test might be considered&#xD;
             by the investigator.&#xD;
&#xD;
          4. No prior chemotherapy for metastatic breast cancer is permitted. Prior administration&#xD;
             of chemotherapy in the adjuvant/neoadjuvant setting is acceptable if completed 6&#xD;
             months before the enrollment.&#xD;
&#xD;
          5. At least one measurable disease according to the response evaluation criteria in solid&#xD;
             tumor (RECIST 1.1)&#xD;
&#xD;
          6. Performance status no more than 1&#xD;
&#xD;
          7. All patients enrolled are required to have adequate hematologic, hepatic, and renal&#xD;
             function&#xD;
&#xD;
          8. Life expectancy longer than 12 weeks&#xD;
&#xD;
          9. No serious medical history of heart, lung, liver and kidney&#xD;
&#xD;
         10. Be able to understand the study procedures and sign informed consent.&#xD;
&#xD;
         11. Patients with good compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women (female patients of child-bearing potential must have a&#xD;
             negative serum pregnancy test within 14 days before the first day of drug dosing, or,&#xD;
             if positive, a pregnancy should be ruled out by ultrasound)&#xD;
&#xD;
          2. Women of child-bearing potential, unwilling to use adequate contraceptive protection&#xD;
             during the process of the study&#xD;
&#xD;
          3. Treatment with radiotherapy at the axial skeleton within 4 weeks before the first&#xD;
             treatment or has not recovered from all toxicities of previous radiotherapy&#xD;
&#xD;
          4. Treatment with an investigational product within 4 weeks before the first treatment&#xD;
&#xD;
          5. Patients with symptomatic central nervous system metastases are not permitted, except&#xD;
             for those with stable and asymptomatic brain metastases who have completed cranial&#xD;
             irradiation, and have at least one measurable lesion outside the brain. Radiotherapy&#xD;
             should be completed within 4 weeks prior to the registration&#xD;
&#xD;
          6. Other active malignancies (including other hematologic malignancies) or other&#xD;
             malignancies within the last 5 years, except for cured nonmelanoma skin cancer or&#xD;
             cervical intraepithelial neoplasia.&#xD;
&#xD;
          7. Patients having a history of clinically significant cardiovascular, hepatic,&#xD;
             respiratory or renal diseases, clinically significant hematological and endocrinal&#xD;
             abnormalities, clinically significant neurological or psychiatric conditions&#xD;
&#xD;
          8. Uncontrolled serious infection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Zhang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Zhang, MD,PhD</last_name>
    <phone>8664175590</phone>
    <phone_ext>85000</phone_ext>
    <email>syner2000@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiqun Du, MD,PhD</last_name>
    <phone>8664175590</phone>
    <phone_ext>85000</phone_ext>
    <email>dyqlh2010@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Zhang, MD,PhD</last_name>
      <phone>+8664175590</phone>
      <phone_ext>85000</phone_ext>
      <email>syner2000@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yiqun Du, MD,PhD</last_name>
      <phone>+8664175590</phone>
      <phone_ext>85000</phone_ext>
      <email>dyqlh2010@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jian Zhang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yiqun Du, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jian Zhang,MD</investigator_full_name>
    <investigator_title>Associate chief physician</investigator_title>
  </responsible_party>
  <keyword>triple negative breast cancer</keyword>
  <keyword>first line chemotherapy</keyword>
  <keyword>Eribulin</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

